[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Michigan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":666},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,177,0,25,[9,50,90,116,139,166,188,209,231,253,275,301,329,356,380,416,448,467,489,516,537,559,585,606,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100647938","empowerment-self-defense-program-for-adult-native-women-survivors-of-sexual-violence-100647938",false,"NCT07712796","Empowerment Self Defense Program for Adult Native Women Survivors of Sexual Violence","Development and Evaluation of a Culturally Grounded Empowerment Self Defense Program for Adult Native Women Survivors of Sexual Violence: Open Pilot Trial","ESD","Inclusion Criteria:\n\n* Identify as Indigenous (including American Indian or Alaska Native), including individuals who identify as multiracial and Indigenous.\n* Identify as a woman, trans woman, and\u002For Two Spirit..\n* Be 18 years of age or older.\n* Have experienced sexual violence or unwanted sexual experiences.\n* Report moderate to high levels of Meet criteria for depression and\u002For PTSD.\n* NOT report high risk for suicidality\n* NOT report active psychosis\n* Live on or near the Pine Ridge Indian Reservation.\n* Be able to read and speak English.\n* Report an ability and willingness to participate in the program sessions and related research activities, including surveys and potential exit interviews.","FEMALE","18 Years",{"count":21,"type":22},14,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to culturally adapt and evaluate an empowerment self-defense (ESD) program (i.e., IMpower) for AI\u002FAN women who have experienced SV in their lifetime and currently experiencing moderate to severe levels of depression and\u002For PTSD symptoms (primary outcomes). Previous research with non-AI\u002FAN women finds that ESD reduces depression and PTSD symptoms, but no research has examined ESD among AI\u002FAN survivors despite calls from our tribal partners to implement ESD with AI\u002FAN adult women survivors. The investigators have assembled an interdisciplinary expert team and Elders\u002FTraditional Knowledge Keepers (TKKs) as well as Survivor Advisory Board (SAB) in the proposed work.",[28,29,30,31,32],"Depression and Quality of Life","Sexual Violence","PTSD","Suicidal Ideation","Problem Drinking",[34,35,36],"Native American","Sexual violence","Depression","NOT_YET_RECRUITING","2026-08-19",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":22},"2026-09-30",{"date":45,"type":22},"2028-06-14",{"name":47,"class":48},"University of Michigan","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":49},"100479797","self-supporting-nasopharyngeal-airway-ssnpa-treating-upper-airway-obstruction-in-hypotonia-100479797","NCT05527652","Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia","Inclusion Criteria:\n\n* Children with Hypotonic Upper Airway Obstruction (HUAO): This includes those who newly diagnosed with obstructive sleep apnea (OSA). These children will undergo overnight polysomnography to determine the presence of OSA (apnea-hypopnea index \\[AHI\\]\\>10 or AHI\\>5 with nocturnal hypoxemia defined as oxygen saturation by pulse oximetry \\[SpO2\\] nadir \\\u003C=75%).\n* All subjects require the presence of at least one symptom of OSA (such as snoring 3 or more nights per week, daytime sleepiness, or hyperactive\u002Finattentive behaviors)\n* Post adenotonsillectomy or those with contraindications to tonsillectomy.\n* Tonsil size 2+ or smaller.\n* Parent\u002Fcaregivers willing and able to provide informed consent and child willing and able to provide assent, where appropriate.\n\nExclusion Criteria:\n\n* AHI ≤10 on polysomnogram (PSG) without hypoxemia or AHI\\\u003C5 with hypoxemia.\n* Any medical reason why Self-Supporting Nasopharyngeal Airway (ssNPA) therapy may not be suitable\n* Active Coronavirus (COVID) 19 infections\n* End-tidal carbon dioxide (ETCO2) or Transcutaneous carbon dioxide (TCO2) values \\>60 mmHg for \\>10% of sleep time on PSG\n* Psychiatric, medical, or social factors likely to invalidate assessments, make adherence with ssNPA highly unlikely or make local follow-up at 8 weeks unfeasible. Some psychiatric conditions may be provoked or exacerbated by OSA, and those most commonly implicated - Attention Deficit\u002FHyperactivity Disorder, Conduct Disorder, and Oppositional Defiant Disorder - will not be exclusions. However, more pervasive conditions such as severe autism will be excluded.\n* Presence of supraglottic airway collapse or more distal airway stenosis or collapse (for example glottic, subglottic stenosis, or concern for distal airway stenosis or malacia)\n* Moderate\u002Fsevere tracheobronchomalacia\n* Need for anticoagulative therapy\n* Bleeding disorder\n* Restrictive thoracic disorders","ALL","3 Years","21 Years",{"count":60,"type":22},40,[25],"The researchers are investigating if the Self-Supporting Nasopharyngeal Airway (ssNPA) device can be used in the treatment of obstructive sleep apnea in children with Hypotonic Upper Airway Obstruction (HUAO).",[64,65,66,67,68,69],"Obstructive Sleep Apnea","Hypertonia, Muscle","Nasal Airway Obstruction","Tolerance","Trisomy 21","Down Syndrome",[71,72,65,73,74,75,76,77,78,79,80,81],"Sleep Apnea Syndromes","Sleep Apnea, Obstructive","Apnea","Respiration Disorders","Respiratory Tract Diseases","Sleep Disorders, Intrinsic","Dyssomnias","Sleep Wake Disorders","Nervous System Diseases","Neuromuscular Manifestations","Neurologic Manifestations","RECRUITING","2026-08-17",{"date":38,"type":41},{"date":86,"type":41},"2022-11-16",{"date":88,"type":22},"2027-08",{"name":47,"class":48},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":56,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":49},"100305759","short-term-implanted-electrodes-following-regenerative-peripheral-nerve-surgery-for-improving-prosthetic-limb-control-signals-100305759","NCT03260400","Short-term Implanted Electrodes Following Regenerative Peripheral Nerve Surgery for Improving Prosthetic Limb Control Signals","Inclusion Criteria:\n\n* Participants must be 22 years of age or older.\n* Participants must have previously undergone an upper limb amputation proximal to the wrist or are scheduled to undergo an upper limb amputation proximal to the wrist.\n* For participants without existing RPNI grafts (at the time of enrollment), the residual limb must have sufficient soft tissue quality to support performance of the RPNI operative procedure. Participants sustaining severe crushing or avulsion injuries with substantial superficial and deep scarring may not be appropriate candidates for inclusion in the study.\n* Participants must be in good health and American Society of Anesthesiologists (ASA) Class I or II (low surgical risk).\n* Participants must have reliable transportation.\n* Participants must be able to attend at minimum 6 hours of experiments per month while electrodes remain implanted.\n* Participants must be at least 6 months post-amputation.\n* Participants who will receive an amputation at the same time as RPNI grafts and electrodes must be undergoing an elective amputation surgery where loss of useful function of the hand has occurred. They must be at least 6 months post-injury or failed limb salvage to participate.\n\nExclusion Criteria:\n\n* Participants may not be suffering from any severe pain syndrome including complex regional pain syndrome or severe phantom pain. All of these conditions would suggest pathological activity of the nerve and would exclude the participant from participation.\n* Participants must not be suffering from any untreated mental health disorders and if they have any DSM-5 diagnoses, they must receive approval to participate from their mental health professional.\n* Participants must not have any medical conditions that, in the opinion of the Principal Investigator, would place them at high risk for a surgical procedure including recent myocardial infarction, cerebrovascular accidents, deep venous thrombosis, pulmonary embolus, uncontrolled diabetes, or end stage renal disease.\n* Participants must not have used tobacco for at least one month prior to enrollment in the study.\n* Participants must agree to not use tobacco for the duration of the study.\n* Participants cannot have sustained bilateral upper extremity amputation.\n* Participants cannot be pregnant.\n* Participants must not have other indwelling electronic implants like pacemakers, implantable cardioverter defibrillators, implantable neurostimulators, body worn insulin pumps, or body worn patient monitoring devices.\n* Participants must not have severe peripheral vascular occlusive disease, venous hypertension of the extremity, or severe lymphedema of the extremity.\n* Participants must not have an autoimmune condition which is not well controlled by medication.\n* Participants will not be considered for enrollment in Primary Upper Limb Amputation with RPNI Grafts and Electrode Implantation if their amputation is a traumatic injury or cancer related","22 Years","75 Years",{"count":99,"type":22},10,[25],"The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.",[103,104],"Amputation Neuroma","Amputation",[106,107],"RPNI","Regenerative Peripheral Nerve Interface","2026-08-15",{"date":110,"type":41},"2026-08-18",{"date":112,"type":41},"2017-12-11",{"date":114,"type":22},"2029-05-05",{"name":47,"class":48},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":56,"minAge":123,"maxAge":19,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":49},"100635049","enlace-familiar-supporting-the-mental-health-of-latino-adolescents-100635049","NCT07547631","Enlace Familiar: Supporting the Mental Health of Latino Adolescents","Enlace Familiar Mental Health Intervention","Our inclusion criteria for youth participation include:\n\n* High school-age adolescents, ages 14-18 who self-identify as Latino\n* Adolescents scoring between 3-12 on the Patient Health Questionnaire-4 (PHQ-4), a brief mental health screening tool for anxiety and depression\n* Adolescents who are not currently receiving mental health treatment or in the past 12 months\n* Adolescents fluent in Spanish or English\n\nOur inclusion criteria for parent participation include:\n\n* Parents of High school-age adolescents, ages 14-18 who completed the intervention (T3)\n* Parents fluent in Spanish or English\n\nOur inclusion criteria for Community Health Worker participation include:\n\n● CHW who implemented our intervention\n\nOur Exclusion Criteria: for youth participation include:\n\n* youth not fluent in English or Spanish\n* youth currently receiving mental health treatment or who have received it in the past year\n\nOur exclusion criteria for parent include:\n\n* parents of High school-age adolescents, ages 14-18 who did not completed the intervention (T3);\n* parents not fluent in Spanish or English\n\nOur exclusion criteria for Community Health Worker participation include\n\n● CHWs not involved in our intervention.","14 Years",{"count":125,"type":22},64,[25],"The goal of this clinical trial is to pilot and evaluate Enlace Familiar, a culturally responsive intervention designed to support Latino adolescents in discussing their mental health needs with caregivers or other trusted adults. The study will examine the feasibility and acceptability of the intervention and examine its potential impact on mental health communication among Latino adolescents ages 14-18 experiencing mental health concerns. Participants will be randomized into two groups, with 32 adolescents assigned to the Enlace Familiar intervention and 32 adolescents assigned to a control condition. The intervention will be implemented in partnership with community health workers (CHWs), who will serve as culturally relevant facilitators.\n\nThe main questions this study aims to answer are:\n\n1. Is Enlace Familiar feasible and acceptable for Latino adolescents when delivered by CHWs?\n2. Does participation in Enlace Familiar improve adolescents' discussions of mental health needs with caregivers or other trusted adults?\n\nParticipants will:\n\n* Complete baseline assessments related to mental health communication, attitudes toward mental health, mental health literacy, and engagement in mental health services.\n* Participate in the Enlace Familiar intervention, delivered by trained CHWs.\n* Complete follow-up assessments to evaluate changes in primary and secondary outcomes.\n* Participate in qualitative interviews or feedback activities to provide information about the acceptability and perceived usefulness of the intervention.\n\nResearchers will use a mixed methods design to evaluate intervention feasibility and acceptability and to explore preliminary changes in adolescent mental health communication following participation in the intervention.",[129],"Mental Health",[131],"Adolescent","2026-08-13",{"date":83,"type":41},{"date":135,"type":22},"2026-10",{"date":137,"type":22},"2029-01",{"name":47,"class":48},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":147,"minAge":19,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":49},"100345992","edrn-prostate-mri-biomarker-study-100345992","NCT03784924","EDRN Prostate MRI Biomarker Study","EDRN Prostate MRI Biomarker Study and Reference Set","P-MRI","Inclusion Criteria:\n\n* Men with suspected but undiagnosed prostate cancer\n* To be scheduled\u002Fscheduled for biopsy as routine clinical care\n\nExclusion Criteria:\n\n* Inability to obtain blood and urine per SOP or conduct an attentive DRE\n* Unable to undergo\u002Ftolerate a prostate MRI or failure to conduct the MRI\n* Prior diagnosis of prostate cancer\n* Prior prostate MRI unless being used as Index MRI (in this case index MRI can be one year prior to consent date)\n* Participating in clinical trial for prostate disease\n* Prior prostate surgery such as TURP, TUNA, TUMT, HOLEP, REZUM, UROlift\n* Prior PCA3, TMPRSS2:erg or MIPS panel performed for clinical purpose","MALE",{"count":149,"type":22},950,"OBSERVATIONAL","The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.",[153,154],"PSA","Prostate Cancer",[156,157,158,159],"Prostate cancer","psa","early detection","MRI",{"date":83,"type":41},{"date":162,"type":41},"2019-02-04",{"date":164,"type":22},"2028-12-31",{"name":47,"class":48},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":49},"100612254","social-media-intervention-for-risky-drinking-100612254","NCT07251192","Social Media Intervention for Risky Drinking","Testing the Efficacy of a New Intervention for High Intensity Drinking Among Emerging Adults","Inclusion Criteria:\n\nReside in the United States of America (USA) Be able to read English, view, and click on a social media advertisement. Self-reported past-month high-intensity drinking (HID) Regular Snapchat use (at least 3 days\u002Fweek).\n\nExclusion Criteria:\n\nFail identity verification (e.g., IP address, survey completion time) Do not provide sufficient contact information Participated in prior pilot study of same intervention","25 Years",{"count":175,"type":22},450,[25],"This study is being completed to test prevention methods to promote wellness and reduce risky behaviors, including the use of substances such as alcohol and other drugs. This study will help the study team learn about ways of delivering this information that is both appealing and helpful to young adults.",[179],"Drinking Behavior","2026-08-12",{"date":182,"type":41},"2026-08-14",{"date":184,"type":22},"2026-08-20",{"date":186,"type":22},"2030-03",{"name":47,"class":48},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":194,"sex":56,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":49},"100555192","using-consumer-grade-wearable-devices-for-fall-risk-evaluation-and-alerts-100555192","NCT06508892","Using Consumer-grade Wearable Devices for Fall Risk Evaluation and Alerts","Inclusion Criteria:\n\n* 65 years or older\n\nExclusion Criteria:\n\n* have been diagnosed with neurological conditions such as multiple sclerosis, Parkinson's disease, traumatic brain injury, Alzheimer's disease, or have had a stroke in the last year\n* have orthopedic or cardiopulmonary conditions and\u002For surgeries in the past year\n* have physical limitations that would make it difficult or uncomfortable for individuals to perform the experimental tasks.",true,"65 Years",{"count":197,"type":22},100,"Creation and use of a smartphone application for older adults to assess the participants' risk of fall. Phase 1: Compare the accuracy and validity of accelerometer and gyroscopic data from a smartphone and gold-standard, wearable sensors gathered during balance and gait activities. Phase 2: Develop a model that integrates wearable sensor data and individual characteristics, such as age, medical conditions, exercises, previous falls, fear of falls, along with gait and balance outcome measurements, to evaluate fall risk in older adults. Phase 3: Integrate the computational model in the design of a mobile app for wearable devices for older adults to self-administer fall risk assessments and provide individualized risk of fall information.",[200],"Mass Screening",[202],"fall risk",{"date":182,"type":41},{"date":205,"type":41},"2024-07-29",{"date":207,"type":22},"2027-12-31",{"name":47,"class":48},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":56,"minAge":216,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":49},"100634759","phase-1-a-pilot-study-of-in-lab-dynamic-standing-in-parkinsons-disease-100634759","NCT07543861","A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease","FOGSTAND","Inclusion Criteria:\n\n* Diagnosis of Parkinson's Disease\n\nExclusion Criteria:\n\n* Inability to stand or walk without an assistive device\n* History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects\n* Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.\n* History of symptomatic cardiovascular or pulmonary disease\n* History of active rheumatic arthritis\n* History of stroke or other neurologic conditions with significant residual sensorimotor deficits\n* History of disabling chronic pain syndrome requiring narcotic analgesics\n* Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \\\u003C24 and significant impairment in activities of daily living)\n* Venous ulcerative stasis or severe varicosities.\n* Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.","50 Years",{"count":218,"type":22},5,[220],"PHASE1","This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.",[223],"Parkinson Disease","2026-08-11",{"date":182,"type":41},{"date":227,"type":41},"2026-05-15",{"date":229,"type":22},"2027-03",{"name":47,"class":48},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":49},"100651838","informing-implementation-of-a-circadian-focused-intervention-for-postpartum-depression-100651838","NCT07766161","Informing Implementation of a Circadian-Focused Intervention for Postpartum Depression","Inclusion Criteria:\n\n1. ≤ 6 months postpartum\n2. EPDS score \\>10\n\nExclusion Criteria:\n\n1. Current or past-year substance use disorder\n2. Lifetime history of bipolar disorder or psychotic disorder\n3. Active suicidal intent\n4. Retinal pathology or history of eye surgery\n5. Current use of photosensitizing medications\n6. Untreated sleep-disordered breathing, untreated restless legs syndrome, or narcolepsy\n7. Psychotherapy or psychotropic medications started\u002Fdose changed in past month (psychotherapy started and\u002For current medication at stable dose ≥ 4 weeks are permitted)\n8. Medical conditions contraindicated for mBLT (e.g., epilepsy\u002Fseizures)",{"count":238,"type":22},30,[25],"The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.",[242],"Postpartum Depression (PPD)",[244,245],"Circadian rhythm","Light therapy","2026-08-10",{"date":182,"type":41},{"date":249,"type":41},"2026-07-29",{"date":251,"type":22},"2027-05",{"name":47,"class":48},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":195,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":49},"100643967","noninvasive-thalamocortical-neuromodulation-with-low-intensity-focused-ultrasound-for-persistent-developmental-stuttering-100643967","NCT07668882","Noninvasive Thalamocortical Neuromodulation With Low-Intensity Focused Ultrasound for Persistent Developmental Stuttering","Inclusion Criteria:\n\n* have normal language, hearing and cognition\n* speak English as their primary language\n* currently stutter\n* score at least 10 (very mild) on the Stuttering Severity Instrument (SSI-4) or exhibit greater than 3% stuttered syllables during at least one of the first 3 speech samples\n* have not receive any treatment for stuttering within the past year\n\nExclusion Criteria:\n\n* History of seizures\n* Major medical or neurological illness (e.g., stroke, serious head trauma, brain infection, Parkinson's disease, etc.)\n* History of closed head injury with loss of consciousness (e.g., concussion)\n* Metal or electronic implants such as cochlear implants and pacemakers\n* Braids or other hair styling that prevents direct access to the scalp (if removal not possible)\n* Current or planned pregnancy\n* Any active, unstable, or inadequately treated psychiatric condition, including but not limited to psychosis, active major depressive episode, bipolar disorder with recent mood episode, or current suicidal ideation.\n* Current use of antipsychotic medications for treatment of a primary psychotic disorder or bipolar disorder; current use of mood stabilizers (e.g., lithium, valproate) or benzodiazepines. Low-dose adjunctive use of atypical antipsychotics (e.g., brexpiprazole, aripiprazole, quetiapine) for treatment-resistant depression or anxiety is not exclusionary if the participant's condition is stable per the existing ≥2-month stability criterion.\n* Any condition or medication that lowers seizure threshold, consistent with standard practice across non-invasive brain stimulation protocols.\n\nNote: participants who cannot undergo MRI may complete the other portions of the study. For participants who cannot undergo MRI can be targeted for LIFU stimulation using a standard T1 scan. Resting state fMRI measures taken before and after stimulation will also be omitted for these cases. But the behavioral and speech measures can still be completed to provide pre and post-stimulation variations.",{"count":260,"type":22},20,[25],"This research is studying the use of low-intensity focused ultrasound (LIFU; a mild, noninvasive acoustic stimulation technique) in a small number of people to learn about its safety as a treatment for stuttering. LIFU is a small, safe sound signal that produces a gentle, pulsing flow of acoustic waves to help different parts of the brain communicate with each other. Researchers want to understand how the mild, non-invasive brain stimulation affects speech relevant brain areas, which may in turn affect speech fluency and speaking-related brain activity in people who stutter.",[264,265],"Stuttering","Developmental Stuttering",[267,268,269],"Low Intensity Focused Ultrasound","Thalamus","Neuromodulation",{"date":180,"type":41},{"date":272,"type":22},"2026-08",{"date":88,"type":22},{"name":47,"class":48},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":300,"locationsCount":49},"100644914","leveraging-interventions-for-needs-and-knowledge-in-diabetes-linkd-100644914","NCT07676188","Leveraging Interventions for Needs and Knowledge in Diabetes (LINKD)","Improving Diabetes Outcomes and Health Disparities by Addressing Unmet Resource Needs- A Sequential Multiple Assignment, Randomized Trial","LINKD","Inclusion Criteria:\n\nParticipants:\n\n* Age: 18 years of age or older\n* Diabetes diagnosis: Documented diagnosis of diabetes (Type 1 or Type 2) with prescribed anti-hyperglycemic medication\n* Glycemic control: Most recent (within the past 6 months) recorded hemoglobin A1c (HbA1c) level of: ≥7.5% for individuals ≤70 years of age and ≥8.0% for individuals between 70-75 years of age Prior study participation: Did not participate in the CareAvenue trial (R01DK116715)\n* Financial burden and\u002For social needs (meeting ONE or more of the following):\n\nPositive report of financial burden using validated screening questions; Medicaid or dual Medicare\u002FMedicaid coverage; Income ≤250% of the federal poverty level; Self-identified as ALICE (Asset-Limited, Income-Constrained, Employed): income above Medicaid threshold but reporting difficulty affording basic needs; Underinsured: high-deductible plan (≥$1,500 individual\u002F$3,000 family) with self-reported difficulty affording healthcare costs; Positive screen for one or more social risk factors on PRAPARE or equivalent (food insecurity, housing instability, transportation barriers, utility insecurity);\n\n* Financial decision-making: Self-identifies as primarily responsible for making own healthcare financial decisions (to address concerns about young adults dependent on family support).\n* Interest in assistance: Expresses interest in receiving assistance with unmet social needs.\n* Ability to participate: Able to complete the screening process in English (or Spanish\u002FArabic if materials available) on behalf of self.\n* Healthcare access: Receives or is able to receive care at Michigan Medicine (required for potential social worker referral).\n\nPeer Supporters:\n\n* Age: 18 years of age or older\n* Diabetes diagnosis: Self-reported diagnosis of diabetes (Type 1 or Type 2)\n* Glycemic control: Within the past 12 months, have had at least one hemoglobin A1c (HbA1c) level of: ≥7.5% for individuals ≤70 years of age and ≥8.0% for individuals ≥71 years of age AND A1c levels \\\u003C7.5% for individuals ≤70 years of age and \\\u003C8.0% for individuals ≥71 years of age\n* Experience navigating social or financial resources: Self-reported success in navigating financial assistance or social services resources\n* Ability to participate: Able to provide peer support in English (option to additionally provide support in Spanish and\u002For Arabic); Able to complete training; Able to make calls every other week with assigned participants; Able to submit call logs; Able to complete a brief survey about experience throughout participation.\n* Confidence in diabetes self-management: Self-reported confidence in ability to manage diabetes\n\nExclusion Criteria:\n\nParticipants:\n\n* Serious psychiatric disorder: Active diagnosis of schizophrenia, active psychosis, or other serious mental illness that would impair ability to engage in intervention (as determined by medical record review)\n* Cognitive impairment: Documented moderate to severe cognitive impairment that would prevent meaningful participation in study activities (as determined by medical record review)\n* Active substance use: Current active illicit drug use that would interfere with study participation (as determined by medical record review)\n* Pregnancy: Currently pregnant or planning pregnancy during the study period (due to expected A1c changes) (as determined by medical record review)\n* Glucose-altering medications: Currently taking medications that alter glucose metabolism as a side effect rather than for diabetes management, including: Chronic oral corticosteroids (≥2 weeks continuous use); Antipsychotic medications known to affect glucose; Other medications affecting glucose when NOT prescribed for diabetes management Note: GLP-1 agonists, SGLT2 inhibitors, and other diabetes medications are NOT excluded, regardless of whether they are also used for weight management\n* Limited life expectancy: Self-reported or documented comorbidity expected to limit life span to less than 3 years\n* Concurrent diabetes study participation: Currently enrolled in another diabetes intervention study\n* Institutionalized: Currently residing in a nursing home, assisted living facility, correctional facility, or another group setting that prevents them from participating on their own behalf\n\nPeer Supporters:\n\n* Cognitive impairment: Self-reported cognitive impairment that would prevent meaningful participation in study activities\n* Participation Concerns or Barriers: Self-reported concerns that would prevent meaningful participation in study activities\n* Limited life expectancy: Self-reported or documented comorbidity expected to limit life span to less than 3 years\n* Institutionalized: Currently residing in a nursing home, assisted living facility, correctional facility, or another group setting that prevents them from participating on their own",{"count":284,"type":22},694,[25],"Unmet social needs and economic burden persist as key reasons why one-third of people with diabetes have poor disease control. The purpose of this study is to learn whether different tools and types of support may help people manage diabetes and related challenges. The study will compare several approaches to understand how they affect people's experiences and health over time. Completion of the study aims will lead to an optimized intervention to improve the health and social well-being of people with diabetes.\n\nParticipants will be randomly assigned to one or more interventions aimed at addressing social and financial needs and will complete multiple surveys over the course of a year. The study team will collect information about their blood pressure and HbA1c (blood glucose).\n\nFindings will advance the field by determining the effectiveness of supportive interventions to address both social needs and diabetes self-care, and by informing protocols for the optimal sequencing of these strategies, a critical evidence gap in healthcare settings.",[288],"Diabetes",[288,290,291,292,293],"Intervention Strategies","Social Support","Financial Support","Disease Management","2026-08-03",{"date":296,"type":41},"2026-08-05",{"date":294,"type":41},{"date":299,"type":22},"2030-07-31",{"name":47,"class":48},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":56,"minAge":308,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":312,"briefSummary":313,"conditions":314,"keywords":318,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":49},"100606702","mobile-platform-for-optimizing-wellness-and-engagement-in-recovery-100606702","NCT07178990","Mobile Platform for Optimizing Wellness and Engagement in Recovery","MPOWER","Inclusion Criteria:\n\n* Participants must be enrolled in the Michigan Medicaid program\n* Opioid agonist treatment (OAT): Participants must have initiated OAT with buprenorphine or methadone\n* Participants must have an OAT prescription and Alcohol use disorder (AUD) based on self-report measure during screening\n* Participants must have regular access to a working smartphone and internet connection.\n* Participants must have a reliable mailing address to receive study supplies (e.g., salivary drug tests).\n\nExclusion Criteria:\n\n* Primary Medicare Coverage: Individuals that are dual-eligible for Medicaid and Medicare and aged 65 or older, due to limited availability of Medicaid claims data for this group\n* Individuals that cannot voluntarily provide informed consent themselves for any reason, including legal incompetency\n* Individuals with substantial cognitive impairment that would interfere with study participation\n* Individuals unable to read or understand English\n* Individuals experiencing active suicidality or psychosis.\n* Individuals with a planned admission to residential treatment or incarceration during the study period.","19 Years","63 Years",{"count":311,"type":22},50,[25],"This pilot study addresses the urgent public health crisis of co-occurring opioid and alcohol use disorders (OUD-AUD), leading causes of mortality in the United States, by testing a scalable digital contingency management (CM) treatment among Medicaid beneficiaries. The study aims to evaluate the feasibility and acceptability of digital CM for OUD-AUD recovery, while also planning for broader implementation.",[315,316,317],"Opioid Agonist Treatment","Alcohol Use Disorder","Opioid Use Disorder",[319,320,321],"Research surveys","App based program","Smartphone",{"date":323,"type":41},"2026-08-06",{"date":325,"type":41},"2025-12-08",{"date":327,"type":22},"2027-07-31",{"name":47,"class":48},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":353,"leadSponsor":355,"locationsCount":49},"100650695","phase-4-outcomes-after-planned-discontinuation-of-antiseizure-medication-100650695","NCT07750496","Outcomes After Planned Discontinuation of AntiSeizure Medication","Study Testing Outcomes After Planned Discontinuation of AntiSeizure Medication","STOP-ASM","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Diagnosis of epilepsy\n* At least 2 years since participants most recent seizure\n* At most 35% calculated 1-year post-discontinuation seizure risk, based upon the existing multivariable calculator if they are on only 1 ASM, otherwise no such restriction if they are more than 1 ASM\n* Willingness to adhere to the study intervention\n* Taking at least 1 antiseizure medication prior to enrollment\n\nExclusion Criteria:\n\n* Current pregnancy or planned pregnancy during the study period\n* History of epilepsy surgery\n* Large space-occupying radiographic lesion such as a large cortical tumor, large artery stroke, or encephalomalacia from traumatic brain injury.\n* Subject has any other clinically significant conditions or circumstances that in the judgment of the investigator or treating clinician should preclude study participation.\n\nPlease note: The researchers will ask participants not to drive for 2 months after ASM discontinuation if on monotherapy, and exercise caution while driving if stopping one antiseizure medication but remaining on others",{"count":60,"type":22},[339],"PHASE4","The main purpose of this study is to understand the effects of continuing versus discontinuing antiseizure medications after a period of seizure-freedom. Physician guidelines endorse that after a period of seizure-freedom, the risk of another seizure may be low enough to allow patients to consider coming off antiseizure medication to see if they still need it. However, evidence is limited regarding how much continuing antiseizure medication still reduces seizures versus increases side effects after a patient has been treated for a while. This study will determine whether discontinuing antiseizure medications benefits patients.",[342],"Epilepsy",[344,345,346,347,348,349],"Seizure","Antiseizure medications","Seizure Free","Feasibility","Acceptability","Discontinue medication","2026-08-02",{"date":323,"type":41},{"date":272,"type":22},{"date":354,"type":22},"2029-08",{"name":47,"class":48},{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":377,"leadSponsor":379,"locationsCount":49},"100650596","mobile-health-intervention-to-increase-activity-in-heart-failure-study-100650596","NCT07750262","Mobile Health Intervention to Increase Activity in Heart Failure Study","MObile Health Intervention to INcrease Activity in Heart Failure Study: A Micro-Randomized Trial","MOVIN-HF","Inclusion Criteria:\n\n* Michigan Medicine patient with a diagnosis of heart failure (HF)\n* Age 18 years and older at screening and able to provide consent\n* New York Heart Association class 2 or 3 HF symptoms\n* Safe for home physical activity as determined by treating clinician\n* Own a smartphone with a compatible Apple or Android operating system\n* Fluent in spoken and written English\n\nExclusion Criteria:\n\n* Hospitalized for HF within the prior 6 weeks\n* Orthopedic or neurological condition significantly limiting physical activity\n* Greater than mild cognitive impairment\n* Enrolled in hospice care\n* Severe valvular stenosis\n* Exercise-induced ventricular tachycardia\n* Obstructive left main or proximal left anterior descending coronary artery disease\n* Pulmonary hypertension treated with inhaled or intravenous therapy\n* Currently pregnant or planning to become pregnant\n* Determined to be unsafe for participation as assessed by the investigative team.",{"count":311,"type":22},[25],"Physical activity is known to help patients with heart failure feel better and live longer though few patients with heart failure are sufficiently active. This study is evaluating whether a mobile health intervention can help patients with heart failure increase physical activity levels and remain active over time. The mobile health intervention consists of three parts: Notifications encouraging physical activity, a digital health coach trained in motivational interviewing, and a mobile application which encourages goal setting and activity monitoring.",[368],"Heart Failure",[370,371,372,373],"Physical activity","Digital health","Mobile Health","Artificial Intelligence","2026-08-01",{"date":323,"type":41},{"date":272,"type":22},{"date":378,"type":22},"2027-11",{"name":47,"class":48},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":388,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":49},"100594660","hemodynamics-after-resistance-training-100594660","NCT07022340","Hemodynamics After Resistance Training","Investigating Resistance Training for Vascular Function and Quality of Life in Perimenopausal Women","HeART","* Are between 40-60 years old\n* Have had menstrual irregularities in the last 12 months\n* Do not currently complete more than two 30-min sessions of structured exercise per week and do not do any resistance training exercise;\n* Are not currently pregnant\n* Do not smoke or vape nicotine or marijuana\n* Have not had an oophorectomy, hysterectomy, or surgical menopause\n* Are not currently taking hormone replacement therapy\n* Have not taken hormone replacement therapy in the last 6 months\n* Are not taking steroidal medication or medication to treat diabetes, cholesterol, or high blood pressure\n* Are able to exercise - your doctor has not told you that you cannot exercise\n* Can attend a morning study visit at the University of Michigan's School of Kinesiology Building\n* Are willing to avoid food 2 hours prior to the morning study visit\n* Are willing to avoid strenuous exercise, caffeine, and alcohol, 8 hours prior to the morning study visit\n* Are willing to participate in an exercise training program or health education program for 16 weeks","40 Years","60 Years",{"count":311,"type":22},[25],"Women's blood vessel health gets worse after menopause, or \"the change of life\". Some women exercise less during menopause. Exercise can improve blood vessel health. The investigators want to know if resistance exercise, like lifting weights, can improve blood vessel health in women who are just starting menopause. The investigators also want to know if lifting weights can improve mood, sleep, and quality of life in women going through menopause. The investigators will have two groups of women for this study. One group will lift weights (do resistance exercise) twice per week, and the other group will get emails with information about menopause. The investigators will measure blood vessel health, sleep, mood, and menopause symptoms at the start and the end of this study and compare women who did and did not exercise.",[394],"Perimenopause",[396,397,398,399,400,401,402,403,404,405,406,407,408],"menopause","perimenopause","vascular function","arterial stiffness","endothelial function","resistance exercise training","strength training","mood","sleep","quality of life","cardiovascular disease","estrogen deficiency","exercise","2026-07-31",{"date":294,"type":41},{"date":412,"type":41},"2025-06-06",{"date":414,"type":22},"2026-12",{"name":47,"class":48},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":194,"sex":56,"minAge":388,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":426,"briefSummary":427,"conditions":428,"keywords":433,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":49},"100640079","motivating-activity-through-text-communications---helping-adults-increase-movement-100640079","NCT07593677","Motivating Activity Through Text Communications - Helping Adults Increase Movement","Motivating Activity Through Text - Comparing Human and AI Messages (MATCH AIM) Trial","MATCH AIM","Inclusion Criteria:\n\n* Be 40 years of age or older\n* Own a smartphone running an Android or iOS operating system\n* Have proficiency with the English language\n* Be capable of providing informed consent\n* Be able to perform moderate physical activity without restrictions\n* Be willing to complete the entire 6-month protocol\n* Be willing to establish a 12-hour window - beginning no later than 9:45 am and ending no later than 9:45 pm - for receiving text messages.\n\nExclusion Criteria:\n\n* Residing outside of the continental United States\n* Self-reporting 90 minutes or more of moderate-to-vigorous intensity physical activity per week\n* contraindications to normal physical activity as identified on the Physical Activity Readiness Questionnaire (PAR-Q)\n* Mobility restrictions that interfere with unassisted physical activity\n* Being pregnant or planning to become pregnant during the study\n* Planning to undergo surgery during the course of the study protocol\n* Having a prior diagnosis of Alzheimer's disease or a related dementia\n* Evidence of mild cognitive impairment as indicated by a mini-Montreal Cognitive Assessment (MoCA) test score of 12 or higher\n* Concurrent participation in another study involving weight loss or physical activity\n* Failure to respond to at least 85% of Ecological Momentary Assessment (EMA) prompts during the 7-day qualification phase.",{"count":425,"type":22},150,[25],"The goal of this clinical trial is to compare the effect of different types of text messages on physical activity levels of middle-aged and older adults and to determine whether these messages are effective in adults age 40 and older who are engaging in less than 90 minutes per week of moderate or higher intensity physical activity. The main questions it aims to answer are:\n\n* Which types of motivational messages show the greatest effects on changes in daily step counts in a 3-month precision text messaging intervention?\n* What are the effects of personalized text messages on automatic affective evaluations, habit strength (experienced automaticity), exercise identity, working memory capacity, and processing speed?\n\nParticipants will:\n\n* Wear a Fitbit activity tracker continuously for 3 months and are encouraged to continue wearing it through 6 months.\n* Wear an activPAL activity monitor on their thigh for 7-day assessment periods at the beginning of the study, at 3 months, and at 6 months.\n* Complete 3 cognitive assessments (\"brain games\") per day on their smartphone during the 7-day assessment periods at baseline, 3 months, and 6 months.\n* Be asked to set goals to increase their daily steps over the first 3 months of the study.\n* Receive up to 4 motivational text messages per day for 3 months to encourage physical activity.\n* Keep study-related apps (Fitbit app, AIM app, MetricWire app) open in the background on their smartphone.\n* Complete questionnaires at the beginning of the study, at 3 months, and at 6 months",[429,430,431,432],"Physical Inactivity","Aging","Cognitive Ability","Behavior Change",[434,435,436,437,438,439,440],"physical activity","behavioral adherence","motivation","cognitive function","aging","older adults","text messaging","2026-07-30",{"date":409,"type":41},{"date":444,"type":41},"2026-05-11",{"date":446,"type":22},"2027-08-02",{"name":47,"class":48},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":49},"100599265","implant-phenotype-modification-via-gbr-and-adm-100599265","NCT07082244","Implant Phenotype Modification Via GBR and ADM","Phenotype Modification Via Guided Bone Regeneration and Acellular Dermal Matrix Simultaneous to Delayed Implant Placement: A Double Arm Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Subjects with a physical status of systemically healthy or suffering from mild to moderate, but well-controlled disease; American Society of Anesthesiology (ASA) I or II.\n* Subjects must have one edentulous region, with at least 3 months of healing post-extraction, in the esthetic zone of the maxilla or the premolar and canine region of the mandible. This region includes the maxillary premolars, canines, and incisors.\n* Subjects must have a full mouth plaque and bleeding score of less than or equal to 20%, measured at four sites per tooth.\n* The patients should have a thin periodontal phenotype; bucco-lingual ridge thickness greater than 6mm.\n* Seibert class I deficiency (Seibert, 1983)\n* Patients willing to sign the informed consent.\n\nExclusion Criteria:\n\n* Presence of uncontrolled and\u002For untreated periodontal disease.\n* Patients currently smoking cigarettes, cannabis, and electronic cigarettes.\n* Subjects taking medications known to impact bone metabolism or have the capacity to affect wound healing. These drugs include bisphosphonates, corticosteroids, parathyroid hormone, RANKL inhibitors, past exposure to head and neck radiation, chemotherapy within the last 12 months, among others.\n* Subjects with systemic diseases that impact bone metabolism and wound healing. Namely, osteoporosis, osteopenia, hyperparathyroidism, Paget's disease.\n* Allergy to the graft materials.\n* Pregnant subjects or individuals who self-report as attempting to become pregnant.\n* Patient's unwilling to sign the informed consent.",{"count":60,"type":22},[25],"Single implant sites with bone loss can often be managed by bone grafting alone. The purpose of this study is to determine whether putting a soft tissue graft substitute over the bone graft will provide an increased benefit for improving the health, appearance, and stability of the bone and gums surrounding the implant.",[459],"Horizontal Ridge Deficiency","2026-07-28",{"date":441,"type":41},{"date":463,"type":41},"2025-06-01",{"date":465,"type":22},"2027-09-01",{"name":47,"class":48},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":49},"100594179","phase-2-inorganic-nitrate-nano3-prevention-of-contrast-associated-acute-kidney-injury-100594179","NCT07016074","Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury","Inclusion Criteria:\n\n* Planned coronary angiogram or contrast-enhanced CT scan.\n* High-risk for contrast-associated acute kidney injury (AKI) with creatine\u002FGlomerular filtration rate (GFR) within 90 days as defined as:\n\n  1. Undergoing coronary angiogram with GFR \\\u003C45 mL\u002Fmin\u002F1.73m2 OR\n  2. Undergoing coronary angiogram with GFR \\\u003C60 mL\u002Fmin\u002F1.73m2 and concurrent risk of AKI as defined by Hamilton et al. BMC2 risk prediction model ≥ 7%.\n\n     OR\n  3. Undergoing contrast-enhanced CT scan with GFR\\\u003C45 mL\u002Fmin\u002F1.73m2\n* If subject is a woman of child-bearing potential, subject agrees to the use of highly effective contraception starting at screening and during study participation.\n* Ability to take oral medication and be willing to adhere to the study intervention regimen.\n* Ability to understand and willingness to agree to an informed consent\n\nExclusion Criteria:\n\n* Already fulfilling definition of acute kidney injury prior to contrast exposure by kidney disease improving global outcomes (KDIGO) criteria (absolute increase in creatinine from baseline of 0.3mg\u002FdL or more OR relative increase in creatine of 50% or more from baseline).\n* Primary indication for Percutaneous Coronary Intervention (PCI) including acute ST-segment elevation myocardial infarction\n* End-stage renal disease actively on dialysis.\n* Received any intravenous or intraarterial contrast within five days from planned contrast administration.\n* Cardiac arrest within 14 days of planned contrast administration.\n* Systolic blood pressure \\\u003C 100mmHg or diastolic blood pressure \\\u003C60mmHg OR currently receiving inotropes or vasopressors for hemodynamic support.\n* History of hypersensitivity or known allergy to any of the components of the investigational product or placebo including sodium nitrate, inorganic nitrate, beet root juice, or lactose. This does not include lactose intolerance.\n* Pregnancy or nursing female\n* Participation in other investigational trials within the past 30 days prior to enrollment.\n* Use of tadalafil within 48 hours, sildenafil or vardenafil within 24 hours, and avanafil within 12 hours of initiation of trial medication. If participant is on continuous dosing of tadalafil, sildenafil, vardenafil, or avanafil, they will be excluded from the trial. If participant is on intermittent dosing of tadalafil, sildenafil, vardenafil, or avanafil, patient agrees to withhold use of medication for duration of medication treatment extending 48 hours after the final dose.",{"count":197,"type":22},[475],"PHASE2","This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.",[478],"Kidney Injury, Acute",[480],"Sodium Nitrate","2026-07-24",{"date":483,"type":41},"2026-07-27",{"date":485,"type":41},"2025-06-30",{"date":487,"type":22},"2026-11",{"name":47,"class":48},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":56,"minAge":495,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":513,"leadSponsor":515,"locationsCount":4},"100648777","regulation-of-platelet-function-in-older-patients-with-atrial-fibrillation-100648777","NCT07724301","Regulation of Platelet Function in Older Patients With Atrial Fibrillation","Inclusion Criteria:\n\n* diagnosed with atrial fibrillation, scheduled for a Watchman Procedure\n\nExclusion Criteria:\n\n* Healthy, taking antiplatelet medication","80 Years",{"count":311,"type":22},"The goal of this observational study is to learn about the effects of antiplatelet drugs on patients over the age of 80 with atrial fibrillation. The main question it aims to answer is:\n\n-Is platelet reactivity effectively controlled in patients over the age of 80 diagnosed with atrial fibrillation following the Watchman procedure.",[499,500],"Atrial Fibrillation","Thrombotic Risk",[502,503,504,505,506,507,508,509],"atrial fibrillation","thrombosis","bleeding","elderly over 80","antiplatelet drugs","aspirin","clopidogrel","platelet function","2026-07-23",{"date":481,"type":41},{"date":272,"type":22},{"date":514,"type":22},"2028-08",{"name":47,"class":48},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":56,"minAge":173,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":49},"100649192","algorithm-informed-decision-making-to-advance-pain-treatment-100649192","NCT07731750","Algorithm-informed Decision-making to Advance Pain Treatment","Algorithm-informed Decision-making to Advance Pain Treatment (ADAPT Study)","ADAPT","Inclusion Criteria:\n\n* Participants must meet the definition of Chronic Low Back Pain (cLBP) described in the NIH Task Force Report on Research Standards for cLBP, i.e., low back pain present at least six months, and present more than half of those days.2\n* Individuals must have a pain interference score of ≥60 on PROMIS Pain Interference. The normal population mean for pain interference is 50. Participants must be 1 standard deviation (SD) above the population mean (\\>=60) for inclusion.\n* Individuals must be willing and eligible to receive at least three of the four proposed interventions.\n* Able to stand for at least 10 minutes\n\nExclusion Criteria:\n\n* Red flags suggesting the presence of an identifiable cause of low back pain, including fever, weight loss, initiation of pain following major trauma, immunosuppression, IV drug use, recent bacterial infection, severe or persistent sensory or motor involvement of bowel, bladder, or lower extremity.\n* Unable to read, write of speak fluent English\n* Visual or hearing difficulties that would preclude participation\n* Active uncontrolled drug\u002Falcohol addiction\n* Individuals receiving new disability or compensation or involved in litigation in the past 12 months.\n* Pregnancy or breastfeeding\n* Individuals on high doses of opioids (over 100 Oral Morphine Equivalents \\[OME\\] per day).\n* Upcoming scheduled back surgery, back surgery within the last year, or more than one back surgery in the past.\n* History of discitis osteomyelitis (spine infection) or spine tumor\n* History of an autoimmune disorder such as ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, or lupus\n* History of cauda equina syndrome or spinal radiculopathy\n* Diagnosis of schizophrenia or schizoaffective diagnosis\n* Diagnosis of any vertebral fracture in the last 6 months\n* Osteoporosis requiring treatment (vitamin D and calcium supplements are acceptable)\n* Cancer\n\n  * History of any bone-related cancer or cancer that metastasized to the bone\n  * Currently in treatment for cancer or plan to start cancer treatment in the next 12 months\n  * History of any cancer treatment in the last 24 months\n* Life expectancy is less than 2 years\n* Current\u002Fplanned (in the next 2 years) enrollment in another study of a device or investigational drug that would interfere with this study, this may include participation in a blinded trial.\n* Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators. This would include but not be limited to severe psychiatric disorders, active suicidal ideations or recent suicide attempts",{"count":525,"type":22},500,[25],"Researchers are exploring how certain personal factors, such as symptoms, health history, and lifestyle, may help predict which treatments will work best for someone.\n\nThe purpose of this study is to evaluate how well a study algorithm chooses the best treatments for a patient when considering their unique pain characteristics.",[529],"Chronic Low-back Pain","2026-07-22",{"date":460,"type":41},{"date":533,"type":22},"2026-07",{"date":535,"type":22},"2030-07",{"name":47,"class":48},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":23,"phases":546,"briefSummary":547,"conditions":548,"keywords":552,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":558,"locationsCount":49},"100609693","phase-2-prophylactic-intravenous-calcium-gluconate-to-decrease-blood-loss-at-time-of-cesarean-delivery-in-pregnant-patients-at-high-risk-for-uterine-atony-100609693","NCT07217899","Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony","Phase II, Randomized, Double Blinded, Placebo Controlled Superiority Trial of Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony","Inclusion Criteria:\n\n* English speaking\n* Viable Intrauterine Pregnancy, Gestational Age ≥24 weeks\n* Labor Converted to Cesarean Delivery at High Risk for Atonic Bleeding Defined as: Any exposure to oxytocin infusion for labor augmentation or induction prior to cesarean delivery\n* Or Scheduled Cesarean Delivery at High Risk for Atonic Bleeding Defined as scheduled Cesarean-Section (CS) plus any one of:\n\n  1. \\> 4 Prior deliveries\n  2. General anesthesia\n  3. Multifetal gestation\n  4. Polyhydramnios diagnosed by ultrasound within 2 weeks\n  5. Macrosomia ≥ 4000gms; estimated fetal weight by palpation or by ultrasound\n  6. Fibroid uterus, defined as: Multiple ≥ 2cm intramural\n  7. Any history of prior Primary postpartum hemorrhage (PPH)\n  8. Platelets \\\u003C 100,000 (but \\>50,000\n  9. Placenta Previa\n  10. Body Mass Index (BMI) ≥ 40\n\nExclusion Criteria:\n\n* Non-English speaking\n* Antenatal suspicion for placenta accreta spectrum\n* History of allergic reaction to Calcium Gluconate\n* Patients with hypertensive disorder of pregnancy receiving Magnesium Sulfate for seizure prophylaxis\n* Underlying Renal Disease defined as Cr\\>1.0\n* Known underlying cardiac condition\n* Cardiac glycosides (Digoxin) within two weeks for maternal or fetal indication\n* Treatment with a calcium channel blocker medication within 24 hours of screening\n* Hypertensive disorder necessitating intravenous antihypertensive medication within 24 hours of screening\n* Emergent case where study participation could impede care (judgement of obstetrician or anesthesiologist)\n* Known hypercalcemia\n* Concurrent use of any drugs that may cause hypercalcemia including\n\n  1. Vitamin D\n  2. Vitamin A\n  3. Thiazide Diuretics\n  4. Calcipotriene\n  5. Teriparatide\n* Ceftriaxone within 48 hours of screening\n* Total Parenteral Nutrition (TPN) within 48 hours of screening\n* Known Coagulopathy International Normalized Ratio (INR) ≥ 1.5\n* Vaginal delivery",{"count":545,"type":22},140,[475],"This research study is being done to learn what effect a single dose of calcium gluconate will have on blood loss at the time of cesarean delivery in pregnancy patients at high risk for uterine atony.",[549,550,551],"Blood Loss, Surgical","Blood Loss, Postoperative","Uterine Atony",[553],"Cesarean delivery",{"date":481,"type":41},{"date":556,"type":41},"2025-10-20",{"date":414,"type":22},{"name":47,"class":48},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":23,"phases":567,"briefSummary":568,"conditions":569,"keywords":573,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":49},"100628048","developing-a-self-management-intervention-to-improve-health-outcomes-for-patients-with-inflammatory-bowel-disease-100628048","NCT07456566","Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease","Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease: Part 3 Pilot Trial","Inclusion Criteria:\n\n* Diagnosis of Inflammatory Bowel Disease (IBD) based on conventional clinical, endoscopic, and histopathological criteria, clinically active IBD\n* Impaired health-related quality of life\n* Clinically active IBD will be indicated by both a modified Harvey Bradshaw Index (HBI) ≥5 for Crohn's disease (CD) or a Simple Clinical Colitis Activity Index (SCCAI) ≥3 for ulcerative colitis (UC)\n* Fecal calprotectin \\> 250 microgram (ug\u002Fg)\n* Impaired IBD-specific health-related quality of life will be defined as a Short IBD Questionnaire score ≤ 60\n\nExclusion Criteria:\n\n* Unable to speak and read English\n* Unable to access the internet regularly by phone or web as this will impair participants ability to engage with the intervention components\n* Have an ileostomy, colostomy, ileoanal pouch, or ileorectal anastomoses\n* Are planned for imminent surgery\n* Have short bowel syndrome\n* Uncontrolled medical or psychiatric disease",{"count":60,"type":22},[25],"This research is studying whether changing an individual's behaviors may have an impact as a treatment or outcome for inflammatory bowel disease. This research will increase the understanding of the role of a self-management program in improving health and health-related quality of life for patients with inflammatory bowel disease.\n\nThe study team hypothesizes:\n\n* the study will achieve a recruitment rate of 10 participants every 3 months\n* 70% participant retention at 24 weeks\n* 70% outcome data collection\n* 70% intervention completion\n* high acceptability",[570,571,572],"Inflammatory Bowel Diseases","Ulcerative Colitis","Crohn Disease",[574,575,576,577],"Digital self-management program","Standard of care","Randomization","Questionnaires","2026-07-21",{"date":510,"type":41},{"date":581,"type":41},"2026-07-20",{"date":583,"type":22},"2028-03",{"name":47,"class":48},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":49},"100530593","virtual-reality-vr--directed-brain-gut-behavioral-treatment-bgbt-for-inflammatory-bowel-disease-ibd-inpatients-100530593","NCT06188793","Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients","Evaluation of a Virtual Reality-Directed Brain Gut Behavioral Treatment Inpatient Program for Patients With Inflammatory Bowel Disease","Inclusion Criteria:\n\n* Patients with Inflammatory Bowel Disease and self-reported pain\n* Hospitalized for management of IBD (inpatient medicine services at Michigan Medicine)\n\nExclusion Criteria:\n\n* Patients that do not report pain\n* Anticipated length of hospital stay is less than 72 hours\n* Patients that have previously had a seizure, loss of awareness, or other symptoms linked to an epileptic condition\n* Patients with binocular vision loss\n* Patients with an uncontrolled cardiac condition such as an arrhythmia, coronary artery disease, or neurological\u002Fcerebrovascular disease.\n* Patients that are currently pregnant",{"count":60,"type":22},[25],"The research is studying virtual reality (VR)-directed brain-gut behavioral therapy (BGBT) as a pain treatment option for hospitalized patients with inflammatory bowel disease (IBD). This study is being done to learn if VR-directed BGBT is feasible and acceptable for patients with IBD in addressing pain in the hospital setting.\n\nThe study hypothesizes that:\n\n* At least 75% of enrolled participants will complete the VR-directed BGBT inpatient program\n* Hospitalized patients with IBD will find VR-directed BGBT acceptable as a pain treatment option in the inpatient setting.",[570],[597,598,599,600],"Virtual reality","Inpatient","Pain","Brain Gut Behavioral Treatment",{"date":510,"type":41},{"date":603,"type":41},"2024-02-13",{"date":414,"type":22},{"name":47,"class":48},{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":194,"sex":56,"minAge":19,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":616,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":49},"100543431","adversity-brain-and-opioid-use-study-100543431","NCT06355778","Adversity, Brain and Opioid Use Study","A Mechanistic Investigation of Risk Factors for Opioid Use Disorder: Examining Hippocampal-based Context-dependent Learning and Memory Associated With Adverse Childhood Experiences","Inclusion Criteria for all groups:\n\n* Fluent in English\n* Able to give informed consent\n* Normal\u002Fcorrected-to-normal vision and hearing\n\nInclusion Criteria for Opioid Use Disorder (OUD) group:\n\n* Diagnosis of OUD\n* Be actively receiving buprenorphine (BUP) for opioid agonist therapy\n* Be free from illicit substance use for at least 2 weeks\n* The study will allow stable dose (\\> 3 months) of commonly prescribed psychiatric medications and some sleep aids (per protocol)\n\nInclusion Criteria for the BUP control group:\n\n* Taking BUP for chronic pain\n* No Substance Use Disorder (including OUD)\n* The study will allow stable dose (\\> 3 months) of commonly prescribed psychiatric medications and some sleep aids (per protocol)\n\nInclusion Criteria for Healthy participant group:\n\n* Not taking BUP\n* Free of any psychiatric or major medical conditions\n\nExclusion Criteria for all groups:\n\n* Pregnancy\n* Significant medical or neurologic conditions (e.g., stroke, seizures, multiple sclerosis)\n* Actively suicidal\n* Contraindication for MRI\n* Inability to tolerate small, enclosed spaces without anxiety or unable to fit comfortably in the MRI scanner\n* Life history of schizophrenia, learning disability, attention deficit disorder, or pervasive developmental disorder\n* Use of substances or prescription medications that could interfere with measures of interest (per protocol)\n* Unable to provide informed consent\n* Participants who have completed other studies in our lab involving learning and memory assessments with the same\u002Fsimilar tasks used here (HUM00230585, HUM00121812) will not be eligible to complete the current study, due to possible learning\u002Fpractice effects","55 Years",{"count":615,"type":22},185,[25],"The way people process and remember information may be related to adverse childhood experiences and Opioid Use Disorder symptoms. The purpose of this project is to examine brain function and performance during learning and memory tasks in adults. The study will compare measures of learning and memory across three groups of participants: those with an Opioid Use Disorder (OUD) that take buprenorphine for opioid replacement therapy, adults without an Opioid Use Disorder taking buprenorphine, and healthy adults that do not have an Opioid Use Disorder and are not taking buprenorphine.",[317,619],"Healthy",[621,622,623,624,625],"Magnetic Resonance Imaging (MRI)","Adverse Childhood Experiences","Fear Learning","Memory","Hippocampal function","2026-07-15",{"date":628,"type":41},"2026-07-17",{"date":630,"type":41},"2025-01-09",{"date":632,"type":22},"2028-04",{"name":47,"class":48},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":194,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":23,"phases":643,"briefSummary":644,"conditions":645,"keywords":648,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":664,"locationsCount":665},"100595584","health-impact-360-advancing-physical-social-and-mental-health-toward-cardiovascular-disease-prevention-in-community-settings-100595584","NCT07034352","Health Impact 360: Advancing Physical, Social, and Mental Health Toward Cardiovascular Disease Prevention in Community Settings","HI360","Inclusion Criteria:\n\n* English or Spanish speaking\n* Able to participate in group-based programming\n\nExclusion Criteria:\n\n\\- All pregnant persons to prevent pregnancy-related biometric changes from biasing outcome analyses",{"count":642,"type":22},328,[25],"The purpose of this clinical trial is to evaluate an evidence-based intervention, Health Impact 360, toward the promotion of cardiovascular health (CVH), including physical, mental, and social health outcomes, among adults living in marginalized communities.\n\nStudy hypotheses include:\n\n* Participants in the Health Impact 360 intervention arm will have better CVH (i.e., a higher overall LE8 score) at the 16-week endpoint compared to the control.\n* Participants in the Health Impact 360 intervention arm will report better mental health (i.e., a lower perceived stress score) at the 16-week endpoint compared to the control.\n* Participants in the Health Impact 360 intervention arm will report better social support and well-being (i.e., higher emotional support and instrumental support scores and reduced social isolation) at the 16-week endpoint compared to control.\n* Participants with greater intervention engagement (e.g., better session attendance) will experience greater intervention impacts across all primary and secondary outcomes relative to the minimally engaged peers.\n\nResearchers will compare outcomes among intervention participants to outcomes among delayed intervention control participants who will be invited to participate in Health Impact 360 once all endpoint measures are collected.\n\nParticipants will:\n\n* Engage in group-based programming twice per week for 8 weeks\n* Engage in group-based programming once per week for 8 weeks\n* Participate in survey-based and biometric data collection at two timepoints: baseline and 16-week endpoint\n* Self-monitor their physical activity via a study-provided pedometer",[646,647],"Health Promotion","Cardiovascular Health",[649,650,651,652,653,654,655,656,657],"Health Program","Health outcomes","Social health","Walking","Health Education and support","Mental health","social support","Health disparities","self management","2026-07-14",{"date":660,"type":41},"2026-07-16",{"date":662,"type":41},"2025-06-20",{"date":414,"type":22},{"name":47,"class":48},7,""]